Alpha Tau Medical Ltd ( (DRTS) ) has issued an announcement.
On March 12, 2025, Alpha Tau Medical Ltd. announced its full-year 2024 financial results and provided a corporate update. The company reported significant progress in clinical trials for its Alpha DaRT technology, including promising interim results in pancreatic cancer and head and neck squamous cell carcinoma trials. The FDA approved an Investigational Device Exemption for a U.S. pilot study of Alpha DaRT in combination with chemotherapy for pancreatic cancer, and the technology was accepted into the FDA’s Total Product Life Cycle Advisory Program to expedite market access for recurrent glioblastoma multiforme. Financially, Alpha Tau reported a net loss of $31.8 million for 2024, with cash reserves expected to support operations for at least two years.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., founded in 2016, is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of Alpha DaRT, a technology designed for the treatment of solid tumors. The technology, initially developed by professors from Tel Aviv University, uses radium-224 to deliver potent alpha-irradiation directly to tumors while sparing surrounding healthy tissue.
YTD Price Performance: -16.13%
Average Trading Volume: 96,113
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $181.8M
Find detailed analytics on DRTS stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com